SCHEMBL608735

SCHEMBL608735

Cc1ccccc1C(=O)N[C@@H](CCCNC(=N)N[N+](=O)[O-])C(=O)N[C@@H](CC(C)C)B1O[C@@H]2C[C@@H]3C[C@@H](C3(C)C)[C@]2(C)O1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 18/20 0.58
PSEN1 P49768 1/20 0.56
PSEN2 P49810 1/20 0.56
APH1B Q8WW43 1/20 0.56
NCSTN Q92542 1/20 0.56
APH1A Q96BI3 1/20 0.56
PSENEN Q9NZ42 1/20 0.56
PSMB11 A5LHX3 9/20 0.54
PSMA7 O14818 9/20 0.54
PSMB1 P20618 9/20 0.54
PSMA1 P25786 9/20 0.54
PSMA2 P25787 9/20 0.54
PSMA3 P25788 9/20 0.54
PSMA4 P25789 9/20 0.54
PSMB8 P28062 9/20 0.54
PSMB9 P28065 9/20 0.54
PSMA5 P28066 9/20 0.54
PSMB4 P28070 9/20 0.54
PSMB6 P28072 9/20 0.54
PSMB10 P40306 9/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL606509 0.93 PSMB5 (0.60) PSMB5PSEN1PSEN2APH1BNCSTN
SCHEMBL606898 0.92 PSEN1 (0.68) PSMB5PSEN1PSEN2APH1BNCSTN
SCHEMBL15628689 0.92 PSMB5 (0.61) PSMB5PSEN1PSEN2APH1BNCSTN
SCHEMBL608741 0.91 PSMB5 (0.57) PSMB5PSEN1PSEN2APH1BNCSTN
SCHEMBL605949 0.90 PSMB5 (0.54) PSMB5PSEN1PSEN2APH1BNCSTN
SCHEMBL606691 0.89 PSMB5 (0.59) PSMB5PSEN1PSEN2APH1BNCSTN
SCHEMBL607054 0.89 PSEN1 (0.53) PSMB5PSEN1PSEN2APH1BNCSTN
SCHEMBL608385 0.89 PSEN1 (0.59) PSMB5PSEN1PSEN2APH1BNCSTN
SCHEMBL606288 0.89 PSMB5 (0.57) PSMB5PSEN1PSEN2APH1BNCSTN
SCHEMBL1477939 0.89 PSMB5 (0.57) PSMB5PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 EP claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 EP claimed
US-8546608-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2013-10-01 US disclosed
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2012-02-16 US disclosed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US disclosed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 PSMB5 2/4885PSEN1 697/4885PSEN2 1334/4885
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 PSMB5 2/4885PSEN1 697/4885PSEN2 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.